Ascentage Pharma Group International (AAPG) Competitors $44.99 +2.54 (+5.98%) As of 08/15/2025 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock AAPG vs. GMAB, ASND, RDY, VTRS, QGEN, MRNA, VRNA, BBIO, BPMC, and ELANShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Its Competitors Genmab A/S Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Qiagen Moderna Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Elanco Animal Health Genmab A/S (NASDAQ:GMAB) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Do analysts prefer GMAB or AAPG? Genmab A/S presently has a consensus target price of $37.60, suggesting a potential upside of 61.30%. Given Genmab A/S's higher probable upside, research analysts plainly believe Genmab A/S is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor GMAB or AAPG? In the previous week, Genmab A/S had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 11 mentions for Genmab A/S and 7 mentions for Ascentage Pharma Group International. Genmab A/S's average media sentiment score of 1.10 beat Ascentage Pharma Group International's score of 0.68 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GMAB or AAPG more profitable? Genmab A/S has a net margin of 37.53% compared to Ascentage Pharma Group International's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Ascentage Pharma Group International's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Ascentage Pharma Group International N/A N/A N/A Do institutionals & insiders have more ownership in GMAB or AAPG? 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, GMAB or AAPG? Genmab A/S has higher revenue and earnings than Ascentage Pharma Group International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B4.79$1.14B$1.9911.71Ascentage Pharma Group International$134.35M31.13-$55.54MN/AN/A SummaryGenmab A/S beats Ascentage Pharma Group International on 12 of the 14 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.18B$3.13B$5.72B$9.79BDividend YieldN/A2.22%3.91%4.13%P/E RatioN/A21.0331.1425.06Price / Sales31.13286.01416.9690.94Price / CashN/A42.6136.7858.67Price / Book93.738.659.086.18Net Income-$55.54M-$54.65M$3.26B$265.11M7 Day Performance7.25%6.56%7.39%4.22%1 Month Performance13.55%4.82%4.22%0.77%1 Year PerformanceN/A15.81%30.30%24.69% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$44.99+6.0%N/AN/A$4.18B$134.35M0.00600News CoverageGap UpGMABGenmab A/S3.9893 of 5 stars$21.43-5.6%$37.80+76.4%-13.5%$14.56B$3.12B10.772,682Positive NewsAnalyst ForecastAnalyst RevisionASNDAscendis Pharma A/S2.4165 of 5 stars$191.49+0.6%$239.80+25.2%+42.8%$11.71B$490.75M-37.111,017High Trading VolumeRDYDr. Reddy's Laboratories2.9376 of 5 stars$13.82+1.6%$16.95+22.7%-13.0%$11.35B$3.81B20.9327,811News CoverageAnalyst RevisionVTRSViatris2.0517 of 5 stars$9.70+3.3%$10.40+7.2%-9.0%$11.02B$14.74B-3.3432,000Insider TradeHigh Trading VolumeQGENQiagen3.654 of 5 stars$48.02-0.7%$49.69+3.5%+8.8%$10.75B$1.98B28.375,765News CoverageMRNAModerna4.3922 of 5 stars$26.12-1.8%$43.59+66.9%-67.7%$10.35B$3.24B-3.475,800Options VolumeVRNAVerona Pharma PLC American Depositary Share2.3795 of 5 stars$105.28-0.1%$109.00+3.5%+282.9%$8.97B$42.28M-106.3430Positive NewsShort Interest ↓BBIOBridgeBio Pharma4.359 of 5 stars$46.58+1.4%$61.35+31.7%+110.3%$8.78B$221.90M-11.39400Insider TradeBPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ELANElanco Animal Health2.914 of 5 stars$16.61+0.8%$16.33-1.7%+24.1%$8.18B$4.44B19.319,000News Coverage Related Companies and Tools Related Companies GMAB Alternatives ASND Alternatives RDY Alternatives VTRS Alternatives QGEN Alternatives MRNA Alternatives VRNA Alternatives BBIO Alternatives BPMC Alternatives ELAN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access